BRPI0414314A - composto de indol contendo sulfonamida cristalino e processo para a preparação do mesmo - Google Patents

composto de indol contendo sulfonamida cristalino e processo para a preparação do mesmo

Info

Publication number
BRPI0414314A
BRPI0414314A BRPI0414314-0A BRPI0414314A BRPI0414314A BR PI0414314 A BRPI0414314 A BR PI0414314A BR PI0414314 A BRPI0414314 A BR PI0414314A BR PI0414314 A BRPI0414314 A BR PI0414314A
Authority
BR
Brazil
Prior art keywords
preparation
compound containing
containing crystalline
indole compound
sulfonamide
Prior art date
Application number
BRPI0414314-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Keiko Takahashi
Kenji Hayashi
Taichi Abe
Takao Omae
Takashi Kato
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of BRPI0414314A publication Critical patent/BRPI0414314A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
BRPI0414314-0A 2003-09-10 2004-09-01 composto de indol contendo sulfonamida cristalino e processo para a preparação do mesmo BRPI0414314A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003318953 2003-09-10
PCT/JP2004/012649 WO2005026118A1 (ja) 2003-09-10 2004-09-01 スルホンアミド含有インドール化合物の結晶およびその製造方法

Publications (1)

Publication Number Publication Date
BRPI0414314A true BRPI0414314A (pt) 2006-10-31

Family

ID=34308544

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414314-0A BRPI0414314A (pt) 2003-09-10 2004-09-01 composto de indol contendo sulfonamida cristalino e processo para a preparação do mesmo

Country Status (24)

Country Link
US (2) US7754894B2 (enExample)
EP (1) EP1666463B1 (enExample)
JP (1) JP4435090B2 (enExample)
KR (1) KR20060120644A (enExample)
CN (2) CN101165049A (enExample)
AT (1) ATE486849T1 (enExample)
AU (1) AU2004272400B2 (enExample)
BR (1) BRPI0414314A (enExample)
CA (1) CA2536995C (enExample)
CY (1) CY1110975T1 (enExample)
DE (1) DE602004029907D1 (enExample)
DK (1) DK1666463T3 (enExample)
ES (1) ES2354286T3 (enExample)
HR (1) HRP20100631T1 (enExample)
IL (2) IL174059A0 (enExample)
MX (1) MXPA06002732A (enExample)
NO (1) NO335256B1 (enExample)
NZ (1) NZ546111A (enExample)
PL (1) PL1666463T3 (enExample)
PT (1) PT1666463E (enExample)
RU (1) RU2336269C2 (enExample)
SI (1) SI1666463T1 (enExample)
TW (1) TW200514770A (enExample)
WO (1) WO2005026118A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005026118A1 (ja) * 2003-09-10 2005-03-24 Eisai Co., Ltd. スルホンアミド含有インドール化合物の結晶およびその製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3868534B2 (ja) * 1996-05-24 2007-01-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド誘導体の製造法および中間体
JP2000247949A (ja) * 1999-02-26 2000-09-12 Eisai Co Ltd スルホンアミド含有インドール化合物
ES2341843T3 (es) * 2000-02-03 2010-06-29 EISAI R&D MANAGEMENT CO., LTD. Inhibidores de la expresion de integrina.
TWI283575B (en) 2000-10-31 2007-07-11 Eisai Co Ltd Medicinal compositions for concomitant use as anticancer agent
WO2005026118A1 (ja) * 2003-09-10 2005-03-24 Eisai Co., Ltd. スルホンアミド含有インドール化合物の結晶およびその製造方法

Also Published As

Publication number Publication date
WO2005026118A1 (ja) 2005-03-24
CN100406440C (zh) 2008-07-30
DK1666463T3 (da) 2010-12-20
TWI349663B (enExample) 2011-10-01
CY1110975T1 (el) 2015-06-11
NO20061545L (no) 2006-06-09
EP1666463B1 (en) 2010-11-03
HRP20100631T1 (hr) 2010-12-31
CA2536995C (en) 2013-12-17
EP1666463A1 (en) 2006-06-07
TW200514770A (en) 2005-05-01
KR20060120644A (ko) 2006-11-27
AU2004272400A1 (en) 2005-03-24
ATE486849T1 (de) 2010-11-15
PL1666463T3 (pl) 2011-04-29
NO335256B1 (no) 2014-10-27
RU2006111454A (ru) 2006-08-27
JPWO2005026118A1 (ja) 2007-11-08
DE602004029907D1 (de) 2010-12-16
PT1666463E (pt) 2011-01-17
IL174059A0 (en) 2006-08-01
US7754894B2 (en) 2010-07-13
US20090247768A1 (en) 2009-10-01
AU2004272400B2 (en) 2010-03-04
US20070082941A1 (en) 2007-04-12
CN1849305A (zh) 2006-10-18
IL196569A0 (en) 2011-07-31
EP1666463A4 (en) 2007-12-12
HK1092796A1 (en) 2007-02-16
MXPA06002732A (es) 2006-06-05
CA2536995A1 (en) 2005-03-24
NZ546111A (en) 2008-11-28
JP4435090B2 (ja) 2010-03-17
CN101165049A (zh) 2008-04-23
SI1666463T1 (sl) 2011-02-28
ES2354286T3 (es) 2011-03-11
RU2336269C2 (ru) 2008-10-20

Similar Documents

Publication Publication Date Title
PT1671949E (pt) Piridinilaminas substituídas
AR047994A1 (es) Formas polimorficas de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidin-2,6-diona
MY132094A (en) Pyrrolo-triazine aniline compounds useful as kinase inhibitors
CY1112780T1 (el) Νεα σουλφονυλοπυρρολια ως αναστολεις της ηdac
BR0110101A (pt) N-acil-sulfonamidas promotoras de apoptose
BR0313108B1 (pt) Processo para preparação de lascas de filme com perfume, lasca de filme com perfume, composição granular para limpeza, e, métodos para melhorar a estabilidade na armazenagem de partículas de perfume e para depositar perfume sobre uma superfície
DK0711280T3 (da) Perhydroisoindolderivater, fremstilling af disse forbindelser og farmaceutiske præparater indeholdende disse forbindelser
MX9200239A (es) Derivados de indol y procedimientos para su preparacion
DK1296976T3 (da) 1,3-dihydro-2H-indol-2-on-derivater og deres anvendelse som lagander for ariginin-vasopressin-receptorerne V1B og V1A
BR0316645A (pt) Derivados de isoindol
HRP20050213A2 (en) 2,4-substituted indoles and their use as 5-ht6 modulators
NO20054787D0 (no) Indenderivater som farmasotiske midler
AU2003273219A1 (en) Novel compositions and methods for the generation of mhc class ii compounds by peptide exchange
BRPI0414314A (pt) composto de indol contendo sulfonamida cristalino e processo para a preparação do mesmo
EA200501557A1 (ru) Новый способ синтеза (2s)-индолин-2-карбоновой кислоты и использование в синтезе периндоприла
EA200501925A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
DE60306747D1 (de) Perindopril enthaltende pharmazeutische zusammensetzung mit oraler dispersion
ZA200601426B (en) Novel method for the synthesis of perindopril and the pharmaceutically-acceptable salts thereof
PL380410A1 (pl) Sposób syntezy perindoprilu i jego farmaceutycznie dopuszczalnych soli
RU2004138299A (ru) Фармацевтическая композиция
SG157401A1 (en) Zeolite synthesis with directing agents with approximately perpendicular groups
WO2007010235A8 (en) Ethanolamine salt of n- (3-methoxy-5-methylpyrazin-2yl) -2- (4- [1 , 3 , 4-0xadiaz0le-2-yl] phenyl) pyridine-3- sulphonamide
EA200600250A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
EA200501669A1 (ru) Замещенные производные индолина и индола
MY149837A (en) New process for the synthesis of perindopril and pharmaceutically acceptable salts thereof

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: C07D 209/42, A61P 35/00, A61P 31/00

Ipc: C07D 209/42 (2011.01)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2477 DE 26-06-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.